{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:56:07Z","timestamp":1793642167048,"version":"4.5.1"},"reference-count":148,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100009104","name":"Department of Health Research, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009104","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["5\/4-4\/189\/M\/2020-NCD-II"],"award-info":[{"award-number":["5\/4-4\/189\/M\/2020-NCD-II"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.dmd.2025.100166","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T20:22:08Z","timestamp":1758572528000},"page":"100166","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The role of cytochrome P450 and gut microbiome in drug metabolism: Insights into Parkinson disease treatment"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2285-3333","authenticated-orcid":false,"given":"Sindduja","family":"Muthukumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0830-6162","authenticated-orcid":false,"given":"Harysh Winster","family":"Suresh Babu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8678-2551","authenticated-orcid":false,"given":"Anto","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brij Mohan","family":"Maurya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iyer","family":"Mahalaxmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukesh Kumar","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dibbanti","family":"HariKrishna Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Arvinder wander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arul","family":"Narayanasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Ganesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Lakhanpal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balachandar","family":"Vellingiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dmd.2025.100166_bib1","series-title":"Parkinson\u2019s Disease and Other Movement Disorders","author":"Edwards","year":"2016"},{"issue":"5","key":"10.1016\/j.dmd.2025.100166_bib2","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00702-023-02617-6","article-title":"The role of tyrosine hydroxylase as a key player in neuromelanin synthesis and the association of neuromelanin with Parkinson\u2019s disease","volume":"130","author":"Nagatsu","year":"2023","journal-title":"J Neural Transm (Vienna)"},{"issue":"6","key":"10.1016\/j.dmd.2025.100166_bib3","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.mcp.2016.11.001","article-title":"Genetics of Parkinson\u2019s disease","volume":"30","author":"Lill","year":"2016","journal-title":"Mol Cell Probes"},{"issue":"suppl 3","key":"10.1016\/j.dmd.2025.100166_bib4","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1002\/ana.10487","article-title":"Genetic and environmental factors in the cause of Parkinson\u2019s disease","volume":"53","author":"Warner","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.dmd.2025.100166_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.envres.2023.116430","article-title":"A deeper understanding about the role of uranium toxicity in neurodegeneration","volume":"233","author":"Vellingiri","year":"2023","journal-title":"Environ Res"},{"key":"10.1016\/j.dmd.2025.100166_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.scitotenv.2023.163483","article-title":"A review of chromium (Cr) epigenetic toxicity and health hazards","volume":"882","author":"Iyer","year":"2023","journal-title":"Sci Total Environ"},{"issue":"11","key":"10.1016\/j.dmd.2025.100166_bib7","doi-asserted-by":"crossref","first-page":"5798","DOI":"10.1007\/s00415-022-11282-w","article-title":"Influence of heavy metals in Parkinson\u2019s disease: an overview","volume":"269","author":"Vellingiri","year":"2022","journal-title":"J Neurol"},{"issue":"2","key":"10.1016\/j.dmd.2025.100166_bib8","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/ng0298-106","article-title":"AlaSOPro mutation in the gene encoding \u03b1-synuclein in Parkinson\u2019s disease","volume":"18","author":"Kr\u00fcger","year":"1998","journal-title":"Nat Genet"},{"issue":"5321","key":"10.1016\/j.dmd.2025.100166_bib9","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the \u03b1-synuclein gene identified in families with Parkinson\u2019s disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.dmd.2025.100166_bib10","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S1474-4422(16)30230-7","article-title":"The epidemiology of Parkinson\u2019s disease: risk factors and prevention","volume":"15","author":"Ascherio","year":"2016","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1016\/j.dmd.2025.100166_bib11","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1001\/archneur.64.7.990","article-title":"Pooled analysis of tobacco use and risk of Parkinson disease","volume":"64","author":"Ritz","year":"2007","journal-title":"Arch Neurol"},{"issue":"6","key":"10.1016\/j.dmd.2025.100166_bib12","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1289\/ehp.0800277","article-title":"Dopamine transporter genetic variants and pesticides in Parkinson\u2019s disease","volume":"117","author":"Ritz","year":"2009","journal-title":"Environ Health Perspect"},{"issue":"1","key":"10.1016\/j.dmd.2025.100166_bib13","doi-asserted-by":"crossref","first-page":"E101","DOI":"10.1208\/aapsj080112","article-title":"Cytochrome P450s and other enzymes in drug metabolism and toxicity","volume":"8","author":"Guengerich","year":"2006","journal-title":"AAPS J"},{"issue":"23","key":"10.1016\/j.dmd.2025.100166_bib14","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.2174\/1568026619666181129124638","article-title":"Biology of heme: drug interactions and adverse drug reactions with CYP450","volume":"18","author":"Kumar","year":"2019","journal-title":"Curr Top Med Chem"},{"issue":"3","key":"10.1016\/j.dmd.2025.100166_bib15","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3390\/jox11030007","article-title":"The central role of cytochrome P450 in xenobiotic metabolism\u2014a brief review on a fascinating enzyme family","volume":"11","author":"Esteves","year":"2021","journal-title":"J Xenobiot"},{"key":"10.1016\/j.dmd.2025.100166_bib16","series-title":"Bioenergetics Theory and Components| Cytochrome P450","author":"Bernhardt","year":"2021"},{"issue":"8","key":"10.1016\/j.dmd.2025.100166_bib17","first-page":"657","article-title":"Mitochondrial biotransformation of drugs and other xenobiotics","volume":"22","author":"Orhan","year":"2021","journal-title":"Curr Drug Metab"},{"issue":"1\u20132","key":"10.1016\/j.dmd.2025.100166_bib18","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.cbi.2006.06.008","article-title":"Mitochondrial P450s","volume":"163","author":"Omura","year":"2006","journal-title":"Chem Biol Interact"},{"issue":"10","key":"10.1016\/j.dmd.2025.100166_bib19","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.drudis.2016.06.004","article-title":"Pathophysiological implications of neurovascular P450 in brain disorders","volume":"21","author":"Ghosh","year":"2016","journal-title":"Drug Discov Today"},{"issue":"1","key":"10.1016\/j.dmd.2025.100166_bib20","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1021\/tx500444e","article-title":"Survey of human oxidoreductases and cytochrome P450 enzymes involved in the metabolism of xenobiotic and natural chemicals","volume":"28","author":"Rendic","year":"2015","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.dmd.2025.100166_bib21","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3389\/fnbeh.2013.00071","article-title":"Acetaldehyde and parkinsonism: role of CYP450 2E1","volume":"7","author":"Vaglini","year":"2013","journal-title":"Front Behav Neurosci"},{"issue":"2","key":"10.1016\/j.dmd.2025.100166_bib22","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/03602532.2018.1439502","article-title":"Cytochrome P450 in the central nervous system as a therapeutic target in neurodegenerative diseases","volume":"50","author":"Navarro-Mabarak","year":"2018","journal-title":"Drug Metab Rev"},{"issue":"2","key":"10.1016\/j.dmd.2025.100166_bib23","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/mdc3.12444","article-title":"Pharmacogenetics of Parkinson\u2019s disease in clinical practice","volume":"4","author":"Corvol","year":"2017","journal-title":"Mov Disord Clin Pract"},{"issue":"2","key":"10.1016\/j.dmd.2025.100166_bib24","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s12024-010-9188-3","article-title":"Review: pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects","volume":"7","author":"Pilgrim","year":"2011","journal-title":"Forensic Sci Med Pathol"},{"issue":"11","key":"10.1016\/j.dmd.2025.100166_bib25","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.3390\/nu12113523","article-title":"Cytochrome P450 metabolism of polyunsaturated fatty acids and neurodegeneration","volume":"12","author":"Sarparast","year":"2020","journal-title":"Nutrients"},{"issue":"3","key":"10.1016\/j.dmd.2025.100166_bib26","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/ana.20051","article-title":"CYP2D6 polymorphism, pesticide exposure, and Parkinson\u2019s disease","volume":"55","author":"Elbaz","year":"2004","journal-title":"Ann Neurol"},{"issue":"7","key":"10.1016\/j.dmd.2025.100166_bib27","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/j.1460-9568.2010.07142.x","article-title":"Cytochrome P450 2D6 enzyme neuroprotects against 1-methyl-4-phenylpyridinium toxicity in SH-SY5Y neuronal cells","volume":"31","author":"Mann","year":"2010","journal-title":"Eur J Neurosci"},{"issue":"3","key":"10.1016\/j.dmd.2025.100166_bib28","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.3390\/ijms24032876","article-title":"Alzheimer\u2019s precision neurology: epigenetics of cytochrome P450 genes in circulating cell-free DNA for disease prediction and mechanism","volume":"24","author":"Bahado-Singh","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.dmd.2025.100166_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1477009","article-title":"SNPs in cytochromes P450 catalyzing cholesterol degradation in brain are associated with Parkinson\u2019s disease","volume":"15","author":"Petkova-Kirova","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.dmd.2025.100166_bib30","article-title":"A CYPome-wide study reveals new potential players in the pathogenesis of Parkinson\u2019s disease","volume":"13","author":"Hartz","year":"2022","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.dmd.2025.100166_bib31","first-page":"159","article-title":"Targeting cytochrome P450 46A1 and brain cholesterol 24-hydroxylation to treat neurodegenerative diseases","volume":"1","author":"Pikuleva","year":"2021","journal-title":"Explor Neuroprotective Ther"},{"key":"10.1016\/j.dmd.2025.100166_bib32","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.neuropharm.2017.06.026","article-title":"Cholesterol-metabolizing enzyme cytochrome P450 46A1 as a pharmacologic target for Alzheimer\u2019s disease","volume":"123","author":"Mast","year":"2017","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.dmd.2025.100166_bib33","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13195-021-00893-6","article-title":"Association of plasma and CSF cytochrome P450, soluble epoxide hydrolase, and ethanolamide metabolism with Alzheimer\u2019s disease","volume":"13","author":"Borkowski","year":"2021","journal-title":"Alzheimers Res Ther"},{"issue":"2","key":"10.1016\/j.dmd.2025.100166_bib34","first-page":"217","article-title":"Huntington\u2019s disease: the past, present, and future search for disease modifiers","volume":"86","author":"Clabough","year":"2013","journal-title":"Yale J Biol Med"},{"issue":"8","key":"10.1016\/j.dmd.2025.100166_bib35","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1093\/brain\/awz174","article-title":"CYP46A1 gene therapy deciphers the role of brain cholesterol metabolism in Huntington\u2019s disease","volume":"142","author":"Kacher","year":"2019","journal-title":"Brain"},{"issue":"17","key":"10.1016\/j.dmd.2025.100166_bib36","doi-asserted-by":"crossref","first-page":"5640","DOI":"10.1074\/jbc.RA119.010727","article-title":"Structure of an ancestral mammalian family 1B1 cytochrome P450 with increased thermostability","volume":"295","author":"Bart","year":"2020","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.dmd.2025.100166_bib37","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1139\/jpn.0261","article-title":"Drug-metabolizing cytochrome P450s in the brain","volume":"27","author":"Miksys","year":"2002","journal-title":"J Psychiatry Neurosci"},{"issue":"8","key":"10.1016\/j.dmd.2025.100166_bib38","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1124\/dmd.119.087718","article-title":"Defining the contribution of CYP1A1 and CYP1A2 to drug metabolism using humanized CYP1A1\/1A2 and Cyp1a1\/Cyp1a2 knockout mice","volume":"47","author":"Kapelyukh","year":"2019","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.dmd.2025.100166_bib39","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1177\/0963689717742662","article-title":"An enriched environment ameliorates oxidative stress and olfactory dysfunction in Parkinson\u2019s disease with \u03b1-synucleinopathy","volume":"27","author":"Wi","year":"2018","journal-title":"Cell Transplant"},{"issue":"3","key":"10.1016\/j.dmd.2025.100166_bib40","doi-asserted-by":"crossref","DOI":"10.1111\/cns.14633","article-title":"CYP1B1 affects the integrity of the blood-brain barrier and oxidative stress in the striatum: an investigation of manganese-induced neurotoxicity","volume":"30","author":"Wu","year":"2024","journal-title":"CNS Neurosci Ther"},{"issue":"1","key":"10.1016\/j.dmd.2025.100166_bib41","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41531-024-00851-7","article-title":"Park7 deletion leads to sex-specific transcriptome changes involving NRF2-CYP1B1 axis in mouse midbrain astrocytes","volume":"11","author":"Helgueta","year":"2025","journal-title":"NPJ Parkinsons Dis"},{"issue":"4","key":"10.1016\/j.dmd.2025.100166_bib42","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1046\/j.1365-2125.2000.00259.x","article-title":"Parkinson\u2019s disease and CYP1A2 activity","volume":"50","author":"Forsyth","year":"2000","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.dmd.2025.100166_bib43","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1080\/004982598238868","article-title":"Molecular genetics of the human cytochrome P450 monooxygenase superfamily","volume":"28","author":"Smith","year":"1998","journal-title":"Xenobiotica"},{"issue":"3","key":"10.1016\/j.dmd.2025.100166_bib44","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.biochi.2007.10.007","article-title":"Xenobiotic metabolizing enzymes in the central nervous system: contribution of cytochrome P450 enzymes in normal and pathological human brain","volume":"90","author":"Dutheil","year":"2008","journal-title":"Biochimie"},{"issue":"12","key":"10.1016\/j.dmd.2025.100166_bib45","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1007\/s11064-017-2384-8","article-title":"Cytochrome P450 2D6 and Parkinson\u2019s disease: polymorphism, metabolic role, risk and protection","volume":"42","year":"2017","journal-title":"Neurochem Res"},{"issue":"16","key":"10.1016\/j.dmd.2025.100166_bib46","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/0024-3205(85)90185-7","article-title":"Comparative behavioral, biochemical and pigmentary effects of MPTP, MPP+ and paraquat in rana pipiens","volume":"37","author":"Barbeau","year":"1985","journal-title":"Life Sci"},{"issue":"8806","key":"10.1016\/j.dmd.2025.100166_bib47","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/0140-6736(92)91196-F","article-title":"Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson\u2019s disease","volume":"339","author":"Smith","year":"1992","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.dmd.2025.100166_bib48","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/j.neurobiolaging.2011.08.014","article-title":"The neuroprotective enzyme CYP2D6 increases in the brain with age and is lower in Parkinson\u2019s disease patients","volume":"33","author":"Mann","year":"2012","journal-title":"Neurobiol Aging"},{"issue":"11","key":"10.1016\/j.dmd.2025.100166_bib49","first-page":"1480","article-title":"CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson\u2019s disease, as revealed from experiments with recombinant enzymes","volume":"29","author":"Hidestrand","year":"2001","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.dmd.2025.100166_bib50","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/BF03033198","article-title":"Characterization and localization of cytochrome P450 mediated metabolism of MPTP to nor-MPTP in mouse brain: relevance to Parkinson\u2019s disease","volume":"3","author":"Upadhya","year":"2001","journal-title":"Neurotox Res"},{"issue":"4","key":"10.1016\/j.dmd.2025.100166_bib51","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3109\/03602532.2015.1101131","article-title":"Impact of physiological, pathological and environmental factors on the expression and activity of human cytochrome P450 2D6 and implications in precision medicine","volume":"47","author":"He","year":"2015","journal-title":"Drug Metab Rev"},{"issue":"1","key":"10.1016\/j.dmd.2025.100166_bib52","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10048-011-0308-3","article-title":"Genome-scale methylation analysis of Parkinson\u2019s disease patients\u2019 brains reveals DNA hypomethylation and increased mRNA expression of cytochrome P450 2E1","volume":"13","author":"Kaut","year":"2012","journal-title":"Neurogenetics"},{"issue":"9","key":"10.1016\/j.dmd.2025.100166_bib53","doi-asserted-by":"crossref","first-page":"698","DOI":"10.2174\/1389200222666210729115151","article-title":"Unveiling the role of cytochrome P450 (2E1) in human brain specifically in Parkinson\u2019s disease-literature review","volume":"22","author":"Shah","year":"2021","journal-title":"Curr Drug Metab"},{"issue":"2\u20133","key":"10.1016\/j.dmd.2025.100166_bib54","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejphar.2009.09.062","article-title":"The ability of cytochrome P450 2D isoforms to synthesize dopamine in the brain: an in vitro study","volume":"626","author":"Bromek","year":"2010","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10.1016\/j.dmd.2025.100166_bib55","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1006\/bbrc.1998.9232","article-title":"Dopamine formation from tyramine by CYP2D6","volume":"249","author":"Hiroi","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"10.1016\/j.dmd.2025.100166_bib56","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/j.1471-4159.2011.07339.x","article-title":"Cytochrome P450 mediates dopamine formation in the brain in vivo","volume":"118","author":"Bromek","year":"2011","journal-title":"J Neurochem"},{"issue":"21","key":"10.1016\/j.dmd.2025.100166_bib57","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1016\/j.jmb.2013.07.015","article-title":"Impacts of variation in the human genome on gene regulation","volume":"425","author":"Haraksingh","year":"2013","journal-title":"J Mol Biol"},{"issue":"12","key":"10.1016\/j.dmd.2025.100166_bib58","doi-asserted-by":"crossref","first-page":"6992","DOI":"10.1007\/s12035-023-03500-x","article-title":"Plausible role of mitochondrial DNA copy number in neurodegeneration\u2014a need for therapeutic approach in Parkinson\u2019s disease (PD)","volume":"60","author":"Venkatesan","year":"2023","journal-title":"Mol Neurobiol"},{"issue":"1","key":"10.1016\/j.dmd.2025.100166_bib59","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/jhg.2011.108","article-title":"Implications of gene copy-number variation in health and diseases","volume":"57","author":"Almal","year":"2012","journal-title":"J Hum Genet"},{"issue":"1","key":"10.1016\/j.dmd.2025.100166_bib60","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12920-019-0556-x","article-title":"Copy number variation profiling in pharmacogenetics CYP-450 and GST genes in Colombian population","volume":"12","author":"Ram\u00edrez","year":"2019","journal-title":"BMC Med Genomics"},{"issue":"4","key":"10.1016\/j.dmd.2025.100166_bib61","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/cpt.690","article-title":"Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects","volume":"102","author":"Zhou","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.dmd.2025.100166_bib62","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1155\/2010\/282130","article-title":"Association of polymorphism in cytochrome P450 2D6 and N-acetyltransferase-2 with Parkinson\u2019s disease","volume":"28","author":"Singh","year":"2010","journal-title":"Dis Markers"},{"issue":"12","key":"10.1016\/j.dmd.2025.100166_bib63","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0084413","article-title":"CYP2D6\u22174 allele polymorphism increases the risk of Parkinson\u2019s disease: evidence from meta-analysis","volume":"8","author":"Lu","year":"2013","journal-title":"PLOS One"},{"issue":"1","key":"10.1016\/j.dmd.2025.100166_bib64","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s41021-017-0078-8","article-title":"Further evidence for the association of CYP2D6\u22174 gene polymorphism with Parkinson\u2019s disease: a case control study","volume":"39","author":"Anwarullah","year":"2017","journal-title":"Genes Environ"},{"issue":"2","key":"10.1016\/j.dmd.2025.100166_bib65","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2174\/138920021502140327175404","article-title":"Genomic and pharmacogenomic biomarkers of Parkinson\u2019s disease","volume":"15","author":"Alonso-Navarro","year":"2014","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.dmd.2025.100166_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1244516","article-title":"SNPs. SNPs in cytochrome P450 genes decide on the fate of individuals with genetic predisposition to Parkinson\u2019s disease","volume":"14","author":"Petkova-Kirova","year":"2023","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/j.dmd.2025.100166_bib67","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.parkreldis.2010.02.012","article-title":"Polymorphisms of caffeine metabolism and estrogen receptor genes and risk of Parkinson\u2019s disease in men and women","volume":"16","author":"Palacios","year":"2010","journal-title":"Parkinsonism Relat Disord"},{"issue":"3\u20134","key":"10.1016\/j.dmd.2025.100166_bib68","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1159\/000450855","article-title":"Gene-environment interaction in Parkinson\u2019s disease: coffee, ADORA2A, and CYP1A2","volume":"47","author":"Chuang","year":"2016","journal-title":"Neuroepidemiology"},{"issue":"5","key":"10.1016\/j.dmd.2025.100166_bib69","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00702-009-0221-1","article-title":"Cytochrome P450 2E1 gene polymorphisms\/haplotypes and Parkinson\u2019s disease in a Swedish population","volume":"116","author":"Shahabi","year":"2009","journal-title":"J Neural Transm (Vienna)"},{"issue":"41","key":"10.1016\/j.dmd.2025.100166_bib70","doi-asserted-by":"crossref","first-page":"35989","DOI":"10.1074\/jbc.M111.254201","article-title":"Identification of a cytochrome P4502E1\/Bid\/C1q-dependent axis mediating inflammation in adipose tissue after chronic ethanol feeding to mice","volume":"286","author":"Sebastian","year":"2011","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.dmd.2025.100166_bib71","doi-asserted-by":"crossref","first-page":"G558","DOI":"10.1152\/ajpgi.00027.2017","article-title":"Ethanol metabolism by alcohol dehydrogenase or cytochrome P450 2E1 differentially impairs hepatic protein trafficking and growth hormone signaling","volume":"313","author":"Doody","year":"2017","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"1","key":"10.1016\/j.dmd.2025.100166_bib72","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0306-4522(99)00533-3","article-title":"Neurochemical changes induced by acute and chronic administration of 1, 2, 3, 4-tetrahydroisoquinoline and salsolinol in dopaminergic structures of rat brain","volume":"96","author":"Antkiewicz-Michaluk","year":"2000","journal-title":"Neuroscience"},{"key":"10.1016\/j.dmd.2025.100166_bib73","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.tox.2015.05.003","article-title":"Cytotoxic mechanism related to dihydrolipoamide dehydrogenase in Leydig cells exposed to heavy metals","volume":"334","author":"Ji","year":"2015","journal-title":"Toxicology"},{"key":"10.1016\/j.dmd.2025.100166_bib74","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.pestbp.2015.01.006","article-title":"Cytochrome P450s\u2014their expression, regulation, and role in insecticide resistance","volume":"120","author":"Liu","year":"2015","journal-title":"Pestic Biochem Physiol"},{"key":"10.1016\/j.dmd.2025.100166_bib75","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.envpol.2016.11.051","article-title":"Effects of triazole fungicides on androgenic disruption and CYP3A4 enzyme activity","volume":"222","author":"Lv","year":"2017","journal-title":"Environ Pollut"},{"issue":"6","key":"10.1016\/j.dmd.2025.100166_bib76","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/ps.3871","article-title":"Metabolism of agrochemicals and related environmental chemicals based on cytochrome P450s in mammals and plants","volume":"71","author":"Ohkawa","year":"2015","journal-title":"Pest Manag Sci"},{"key":"10.1016\/j.dmd.2025.100166_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.ecoenv.2022.113972","article-title":"Neurotoxicity of pesticides\u2014a link to neurodegeneration","volume":"243","author":"Vellingiri","year":"2022","journal-title":"Ecotoxicol Environ Saf"},{"issue":"8","key":"10.1016\/j.dmd.2025.100166_bib78","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.freeradbiomed.2012.02.005","article-title":"Resveratrol potentiates cytochrome P450 2d22-mediated neuroprotection in maneb- and paraquat-induced parkinsonism in the mouse","volume":"52","author":"Srivastava","year":"2012","journal-title":"Free Radic Biol Med"},{"issue":"5","key":"10.1016\/j.dmd.2025.100166_bib79","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1007\/s12035-016-9938-7","article-title":"Monocrotophos induces the expression of xenobiotic metabolizing cytochrome P450s (CYP2C8 and CYP3A4) and neurotoxicity in human brain cells","volume":"54","author":"Tripathi","year":"2017","journal-title":"Mol Neurobiol"},{"issue":"12","key":"10.1016\/j.dmd.2025.100166_bib80","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.3109\/10715762.2010.512041","article-title":"Effects of cypermethrin on monoamine transporters, xenobiotic metabolizing enzymes and lipid peroxidation in the rat nigrostriatal system","volume":"44","author":"Tiwari","year":"2010","journal-title":"Free Radic Res"},{"key":"10.1016\/j.dmd.2025.100166_bib81","volume":"95","author":"Ingelman-Sundberg","year":"2022"},{"issue":"1612","key":"10.1016\/j.dmd.2025.100166_bib82","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2012.0431","article-title":"Human cytochromes P450 in health and disease","volume":"368","author":"Nebert","year":"2013","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"8","key":"10.1016\/j.dmd.2025.100166_bib83","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s40262-021-01032-y","article-title":"Contribution of the gut microbiome to drug disposition, pharmacokinetic and pharmacodynamic variability","volume":"60","author":"Tsunoda","year":"2021","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.dmd.2025.100166_bib84","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.apsb.2021.01.009","article-title":"Gut microbiota mediates the absorption of FLZ, a new drug for Parkinson\u2019s disease treatment","volume":"11","author":"Shang","year":"2021","journal-title":"Acta Pharm Sin B"},{"issue":"42","key":"10.1016\/j.dmd.2025.100166_bib85","doi-asserted-by":"crossref","first-page":"26261","DOI":"10.1074\/jbc.271.42.26261","article-title":"Protein kinase C modulates regulation of the CYP1A1 gene by the aryl hydrocarbon receptor","volume":"271","author":"Chen","year":"1996","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.dmd.2025.100166_bib86","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/humu.21132","article-title":"Analysis of human CYP1A1 and CYP1A2 genes and their shared bidirectional promoter in eight world populations","volume":"31","author":"Jorge-Nebert","year":"2010","journal-title":"Hum Mutat"},{"issue":"3","key":"10.1016\/j.dmd.2025.100166_bib87","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/mds.27581","article-title":"Unraveling gut microbiota in Parkinson\u2019s disease and atypical parkinsonism","volume":"34","author":"Barichella","year":"2019","journal-title":"Mov Disord"},{"issue":"suppl 2","key":"10.1016\/j.dmd.2025.100166_bib88","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000518147","article-title":"Parkinson\u2019s disease and gut microbiota","volume":"77","author":"Hirayama","year":"2021","journal-title":"Ann Nutr Metab"},{"issue":"1","key":"10.1016\/j.dmd.2025.100166_bib89","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jbiotec.2006.01.026","article-title":"Cytochromes P450 as versatile biocatalysts","volume":"124","author":"Bernhardt","year":"2006","journal-title":"J Biotechnol"},{"issue":"6","key":"10.1016\/j.dmd.2025.100166_bib90","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s40495-019-00200-w","article-title":"Microbiome is a functional modifier of P450 drug metabolism","volume":"5","author":"Dempsey","year":"2019","journal-title":"Curr Pharmacol Rep"},{"issue":"1","key":"10.1016\/j.dmd.2025.100166_bib91","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1146\/annurev-genom-090711-163814","article-title":"The human microbiome: our second genome","volume":"13","author":"Grice","year":"2012","journal-title":"Annu Rev Genom Hum Genet"},{"issue":"8","key":"10.1016\/j.dmd.2025.100166_bib92","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1124\/dmd.114.058040","article-title":"The revised human liver cytochrome P450 \u201cPie\u201d: absolute protein quantification of CYP4F and CYP3A enzymes using targeted quantitative proteomics","volume":"42","author":"Michaels","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmd.2025.100166_bib93","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/03602532.2018.1497647","article-title":"Gut microbiota modulates drug pharmacokinetics","volume":"50","author":"Zhang","year":"2018","journal-title":"Drug Metab Rev"},{"issue":"1","key":"10.1016\/j.dmd.2025.100166_bib94","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1038\/s41467-018-05767-4","article-title":"The gut microbiota promotes hepatic fatty acid desaturation and elongation in mice","volume":"9","author":"Kindt","year":"2018","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.dmd.2025.100166_bib95","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/00498250802651984","article-title":"Intestinal flora induces the expression of Cyp3a in the mouse liver","volume":"39","author":"Toda","year":"2009","journal-title":"Xenobiotica"},{"issue":"1","key":"10.1016\/j.dmd.2025.100166_bib96","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.apsb.2019.12.001","article-title":"The gut microbiome: an orchestrator of xenobiotic metabolism","volume":"10","author":"Collins","year":"2020","journal-title":"Acta Pharm Sin B"},{"issue":"2","key":"10.1016\/j.dmd.2025.100166_bib97","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/mnfr.201200364","article-title":"Prebiotic approach alleviates hepatic steatosis: implication of fatty acid oxidative and cholesterol synthesis pathways","volume":"57","author":"Pachikian","year":"2013","journal-title":"Mol Nutr Food Res"},{"issue":"22","key":"10.1016\/j.dmd.2025.100166_bib98","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1101\/gad.850400","article-title":"Role of LXRs in control of lipogenesis","volume":"14","author":"Schultz","year":"2000","journal-title":"Genes Dev"},{"issue":"1","key":"10.1016\/j.dmd.2025.100166_bib99","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s10020-021-00407-y","article-title":"Nuclear receptors: a bridge linking the gut microbiome and the host","volume":"27","author":"Wang","year":"2021","journal-title":"Mol Med"},{"issue":"3","key":"10.1016\/j.dmd.2025.100166_bib100","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1124\/mol.107.040741","article-title":"Identification of oxysterol 7\u03b1-hydroxylase (Cyp7b1) as a novel retinoid-related orphan receptor \u03b1 (ROR\u03b1)(NR1F1) target gene and a functional cross-talk between ROR\u03b1 and liver X receptor (NR1H3)","volume":"73","author":"Wada","year":"2008","journal-title":"Mol Pharmacol"},{"issue":"18","key":"10.1016\/j.dmd.2025.100166_bib101","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.3390\/ijms20184522","article-title":"Oxysterols in autoimmunity","volume":"20","author":"Duc","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.dmd.2025.100166_bib102","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.685594","article-title":"The cerebrospinal fluid profile of cholesterol metabolites in Parkinson\u2019s disease and their association with disease state and clinical features","volume":"13","author":"Griffiths","year":"2021","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.dmd.2025.100166_bib103","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.bbi.2013.07.007","article-title":"Cerebrospinal fluid inflammatory markers in Parkinson\u2019s disease\u2013associations with depression, fatigue, and cognitive impairment","volume":"33","author":"Lindqvist","year":"2013","journal-title":"Brain Behav Immun"},{"issue":"5","key":"10.1016\/j.dmd.2025.100166_bib104","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nchembio782","article-title":"Elevated levels of oxidized cholesterol metabolites in lewy body disease brains accelerate \u03b1-synuclein fibrilization","volume":"2","author":"Bosco","year":"2006","journal-title":"Nat Chem Biol"},{"issue":"6","key":"10.1016\/j.dmd.2025.100166_bib105","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1007\/s00204-024-03710-9","article-title":"Formation of potentially toxic metabolites of drugs in reactions catalyzed by human drug-metabolizing enzymes","volume":"98","author":"Rendic","year":"2024","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.dmd.2025.100166_bib106","first-page":"235","article-title":"The role of CYP2E1 in alcohol metabolism and sensitivity in the central nervous system","volume":"67","author":"Heit","year":"2013"},{"issue":"2","key":"10.1016\/j.dmd.2025.100166_bib107","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.toxlet.2010.06.023","article-title":"Aquaporin-4 knockout enhances astrocyte toxicity induced by 1-methyl-4-phenylpyridinium ion and lipopolysaccharide via increasing the expression of cytochrome P4502E1","volume":"198","author":"Hao","year":"2010","journal-title":"Toxicol Lett"},{"issue":"5","key":"10.1016\/j.dmd.2025.100166_bib108","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.bpg.2017.10.006","article-title":"The interaction between smoking, alcohol and the gut microbiome","volume":"31","author":"Capurso","year":"2017","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.dmd.2025.100166_bib109","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.parkreldis.2019.08.010","article-title":"The gut microbiota: a novel therapeutic target in Parkinson\u2019s disease?","volume":"66","author":"Lubomski","year":"2019","journal-title":"Parkinsonism Relat Disord"},{"issue":"6","key":"10.1016\/j.dmd.2025.100166_bib110","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.893","article-title":"Normal variation of the gut microbiota affects hepatic cytochrome P450 activity in mice","volume":"9","author":"Togao","year":"2021","journal-title":"Pharmacol Res Perspect"},{"issue":"1","key":"10.1016\/j.dmd.2025.100166_bib111","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41531-020-0112-6","article-title":"Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens","volume":"6","author":"Wallen","year":"2020","journal-title":"npj Parkinson Dis"},{"issue":"1","key":"10.1016\/j.dmd.2025.100166_bib112","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1046\/j.1365-2044.1999.00602.x","article-title":"The physiological and pharmacological roles of cytochrome P450 isoenzymes","volume":"54","author":"Chang","year":"1999","journal-title":"Anaesthesia"},{"issue":"7","key":"10.1016\/j.dmd.2025.100166_bib113","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1517\/17425255.2013.789018","article-title":"Anti-Parkinson\u2019s disease drugs and pharmacogenetic considerations","volume":"9","author":"Ag\u00fandez","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"10.1016\/j.dmd.2025.100166_bib114","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00702-020-02150-w","article-title":"Rasagiline and selegiline modulate mitochondrial homeostasis, intervene apoptosis system and mitigate \u03b1-synuclein cytotoxicity in disease-modifying therapy for Parkinson\u2019s disease","volume":"127","author":"Naoi","year":"2020","journal-title":"J Neural Transm (Vienna)"},{"key":"10.1016\/j.dmd.2025.100166_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115308","article-title":"Design, synthesis and evaluation of novel monoamine oxidase B (MAO-B) inhibitors with improved pharmacokinetic properties for Parkinson\u2019s disease","volume":"252","author":"Yi","year":"2023","journal-title":"Eur J Med Chem"},{"issue":"13","key":"10.1016\/j.dmd.2025.100166_bib116","first-page":"4514","article-title":"Converging dopaminergic neurotoxicity mechanisms of antipsychotics, methamphetamine and levodopa","volume":"25","author":"Zareifopoulos","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"5","key":"10.1016\/j.dmd.2025.100166_bib117","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1007\/s12325-022-02097-2","article-title":"P2B001 (extended release pramipexole and rasagiline): a new treatment option in development for Parkinson\u2019s disease","volume":"39","author":"Hauser","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.dmd.2025.100166_bib118","series-title":"The Metabolism of Levodopa: Why Are Cytochrome P450 Enzymes Being Ignored?","author":"Wright","year":"2019"},{"issue":"5","key":"10.1016\/j.dmd.2025.100166_bib119","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/01.NPR.0000660368.67226.ad","article-title":"Ciprofloxacin-rasagiline drug interaction leading to dopaminergic effects","volume":"45","author":"Chappell","year":"2020","journal-title":"Nurse Pract"},{"issue":"9","key":"10.1016\/j.dmd.2025.100166_bib120","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1021\/acsomega.0c00123","article-title":"Preclinical herb\u2013drug pharmacokinetic interaction of panax ginseng extract and selegiline in freely moving rats","volume":"5","author":"Yang","year":"2020","journal-title":"ACS Omega"},{"issue":"7","key":"10.1016\/j.dmd.2025.100166_bib121","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.ctrv.2012.12.008","article-title":"Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb\u2013drug interactions in cancer patients","volume":"39","author":"Goey","year":"2013","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"10.1016\/j.dmd.2025.100166_bib122","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF03190594","article-title":"In vitro formation of selegiline-N-oxide as a metabolite of selegiline in human, hamster, mouse, rat, guinea-pig, rabbit and dog","volume":"29","author":"L\u00e9vai","year":"2004","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"9","key":"10.1016\/j.dmd.2025.100166_bib123","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1124\/dmd.31.9.1093","article-title":"Comparative studies on the cytochrome P450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems","volume":"31","author":"Salonen","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100166_bib124","article-title":"Resveratrol: a novel drug for the management of neurodegenerative disorders","volume":"230","author":"Bala S [Editor3] S","year":"2023"},{"issue":"10","key":"10.1016\/j.dmd.2025.100166_bib125","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.2174\/0929866527666200403110036","article-title":"Resveratrol regulates Nrf2-mediated expression of antioxidant and xenobiotic metabolizing enzymes in pesticides-induced parkinsonism","volume":"27","author":"Rasheed","year":"2020","journal-title":"Protein Pept Lett"},{"key":"10.1016\/j.dmd.2025.100166_bib126","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2020.213740","article-title":"Fluorescent probes for the detection and imaging of cytochrome P450","volume":"437","author":"Feng","year":"2021","journal-title":"Coord Chem Rev"},{"key":"10.1016\/j.dmd.2025.100166_bib127","article-title":"Hydroxypropyl-\u03b2-cyclodextrin-complexed resveratrol protects A53T transgenic Parkinson\u2019s disease mice via modulating signaling pathways of the microbiota-gut-brain axis","author":"Sang","year":"2023","journal-title":"Research Square"},{"issue":"13","key":"10.1016\/j.dmd.2025.100166_bib128","doi-asserted-by":"crossref","first-page":"947","DOI":"10.2165\/00023210-200317130-00002","article-title":"Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists","volume":"17","author":"Bentu\u00e9-Ferrer","year":"2003","journal-title":"CNS Drugs"},{"issue":"9","key":"10.1016\/j.dmd.2025.100166_bib129","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1080\/14740338.2020.1804550","article-title":"Safety considerations when using non-ergot dopamine agonists to treat Parkinson\u2019s disease","volume":"19","author":"Stocchi","year":"2020","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"10.1016\/j.dmd.2025.100166_bib130","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/toxsci\/kfy101","article-title":"Effect of the catechol-O-methyltransferase inhibitors tolcapone and entacapone on fatty acid metabolism in HepaRG cells","volume":"164","author":"Gr\u00fcnig","year":"2018","journal-title":"Toxicol Sci"},{"issue":"2","key":"10.1016\/j.dmd.2025.100166_bib131","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2125.2008.03334.x","article-title":"Influence of domperidone on pharmacokinetics, safety and tolerability of the dopamine agonist Rotigotine","volume":"67","author":"Braun","year":"2009","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.dmd.2025.100166_bib132","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2174\/187231210791292735","article-title":"Characterization of CYP3A isozymes involved in the metabolism of domperidone: role of cytochrome b5 and inhibition by ketoconazole","volume":"4","author":"Michaud","year":"2010","journal-title":"Drug Metab Lett"},{"issue":"11\u201312","key":"10.1016\/j.dmd.2025.100166_bib133","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1080\/00498250400015301","article-title":"Identification of the cytochrome P450 enzymes involved in the metabolism of domperidone","volume":"34","author":"Simard","year":"2004","journal-title":"Xenobiotica"},{"key":"10.1016\/j.dmd.2025.100166_bib134","doi-asserted-by":"crossref","first-page":"304","DOI":"10.20517\/jtgg.2022.08","article-title":"Neurogenic dysphagia: current pharmacogenomic perspectives","volume":"6","author":"Guerra","year":"2022","journal-title":"J Transl Genet Genom"},{"key":"10.1016\/j.dmd.2025.100166_bib135","series-title":"Cytochrome P450","first-page":"61","article-title":"Localization of cytochrome P450 in membranes: mitochondria","author":"Omura","year":"1993"},{"issue":"2","key":"10.1016\/j.dmd.2025.100166_bib136","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.tiv.2010.11.019","article-title":"Mitochondrial CYP2E1 is sufficient to mediate oxidative stress and cytotoxicity induced by ethanol and acetaminophen","volume":"25","author":"Knockaert","year":"2011","journal-title":"Toxicol In Vitro"},{"issue":"2\u20133","key":"10.1016\/j.dmd.2025.100166_bib137","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.tox.2012.08.009","article-title":"Induction of brain CYP2E1 by chronic ethanol treatment and related oxidative stress in hippocampus, cerebellum, and brainstem","volume":"302","author":"Zhong","year":"2012","journal-title":"Toxicology"},{"issue":"2","key":"10.1016\/j.dmd.2025.100166_bib138","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/jbm.a.34705","article-title":"Neurotoxicity and gene-expressed profile in brain-injured mice caused by exposure to titanium dioxide nanoparticles","volume":"102","author":"Ze","year":"2014","journal-title":"J Biomed Mater Res A"},{"issue":"14","key":"10.1016\/j.dmd.2025.100166_bib139","doi-asserted-by":"crossref","first-page":"9936","DOI":"10.1074\/jbc.M113.525659","article-title":"Mitochondrial targeting of cytochrome P450 (CYP) 1B1 and its role in polycyclic aromatic hydrocarbon-induced mitochondrial dysfunction","volume":"289","author":"Bansal","year":"2014","journal-title":"J Biol Chem"},{"issue":"26","key":"10.1016\/j.dmd.2025.100166_bib140","doi-asserted-by":"crossref","first-page":"10336","DOI":"10.1074\/jbc.RA119.008848","article-title":"Mitochondrially targeted cytochrome P450 2D6 is involved in monomethylamine-induced neuronal damage in mouse models","volume":"294","author":"Chattopadhyay","year":"2019","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.dmd.2025.100166_bib141","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/ejn.15566","article-title":"Bioactive lipids and their metabolism: new therapeutic opportunities for Parkinson\u2019s disease","volume":"55","author":"Shen","year":"2022","journal-title":"Eur J Neurosci"},{"issue":"23","key":"10.1016\/j.dmd.2025.100166_bib142","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.3390\/cells11233736","article-title":"Levodopa-induced dyskinesia in Parkinson\u2019s disease: pathogenesis and emerging treatment strategies","volume":"11","author":"Kwon","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.dmd.2025.100166_bib143","author":"Wright"},{"issue":"2","key":"10.1016\/j.dmd.2025.100166_bib144","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1586\/14737175.2014.877840","article-title":"Novel levodopa formulations in the treatment of Parkinson\u2019s disease","volume":"14","author":"Pilleri","year":"2014","journal-title":"Expert Rev Neurother"},{"issue":"1","key":"10.1016\/j.dmd.2025.100166_bib145","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3390\/molecules23010040","article-title":"Dopamine and levodopa prodrugs for the treatment of Parkinson\u2019s disease","volume":"23","author":"Haddad","year":"2017","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.dmd.2025.100166_bib146","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1177\/106002800303700207","article-title":"Pseudo-Parkinson disease secondary to ritonavir\u2013buspirone interaction","volume":"37","author":"Clay","year":"2003","journal-title":"Ann Pharmacother"},{"issue":"6","key":"10.1016\/j.dmd.2025.100166_bib147","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.1074\/jbc.M112.402123","article-title":"Metabolism of 1-methyl-4-phenyl-1,2, 3, 6-tetrahydropyridine by mitochondrion-targeted cytochrome P450 2D6: implications in Parkinson disease","volume":"288","author":"Bajpai","year":"2013","journal-title":"J Biol Chem"},{"issue":"8","key":"10.1016\/j.dmd.2025.100166_bib148","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.neuropharm.2009.03.003","article-title":"MPTP-induced model of Parkinson\u2019s disease in cytochrome P450 2E1knockout mice","volume":"56","author":"Viaggi","year":"2009","journal-title":"Neuropharmacology"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625094759?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625094759?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:56:17Z","timestamp":1763754977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955625094759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":148,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0090955625094759"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100166","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of cytochrome P450 and gut microbiome in drug metabolism: Insights into Parkinson disease treatment","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100166","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100166"}}